<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:43:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3293124" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3293124</identifier>
        <datestamp>2012-03-05</datestamp>
        <setSpec>jcbfm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Cereb Blood Flow Metab</journal-id>
              <journal-title-group>
                <journal-title>Journal of Cerebral Blood Flow &amp; Metabolism</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0271-678X</issn>
              <issn pub-type="epub">1559-7016</issn>
              <publisher>
                <publisher-name>Nature Publishing Group</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3293124</article-id>
              <article-id pub-id-type="pmcid">PMC3293124</article-id>
              <article-id pub-id-type="pmc-uid">3293124</article-id>
              <article-id pub-id-type="pmid">22186668</article-id>
              <article-id pub-id-type="pii">jcbfm2011184</article-id>
              <article-id pub-id-type="doi">10.1038/jcbfm.2011.184</article-id>
              <article-id pub-id-type="pmid">22186668</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Brief Communication</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an <italic>in vivo</italic> [<sup>11</sup>C]-harmine positron emission tomography study</article-title>
                <alt-title alt-title-type="running">Rapid MAO-A binding change after altered substrate</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sacher</surname>
                    <given-names>Julia</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rabiner</surname>
                    <given-names>Eugenii A</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clark</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rusjan</surname>
                    <given-names>Pablo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Soliman</surname>
                    <given-names>Alexandra</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boskovic</surname>
                    <given-names>Rada</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff4">4</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kish</surname>
                    <given-names>Stephen J</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Alan A</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Houle</surname>
                    <given-names>Sylvain</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meyer</surname>
                    <given-names>Jeffrey H</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                  <xref ref-type="corresp" rid="caf1">*</xref>
                </contrib>
                <aff id="aff1"><label>1</label><institution>Vivian M Rakoff PET Imaging Centre</institution>, Toronto, <country>Canada</country></aff>
                <aff id="aff2"><label>2</label><institution>Mood and Anxiety Disorders Division, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto</institution>, Toronto, <country>Canada</country></aff>
                <aff id="aff3"><label>3</label><institution>Day Clinic of Cognitive Neurology, University of Leipzig and Max-Planck-Institute for Cognition and Brain Sciences</institution>, Leipzig, <country>Germany</country></aff>
                <aff id="aff4"><label>4</label><institution>GlaxoSmithKline</institution>, Toronto, <country>Canada</country></aff>
                <aff id="aff5"><label>5</label><institution>The Clinical Pharmacology and Toxicology Division, The Hospital for Sick Children, University of Toronto</institution>, Toronto, <country>Canada</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="caf1"><label>*</label>250 College Street, Toronto, Ontario M5T1R8, <country>Canada</country>. E-mail: <email>jeff.meyer@camhpet.ca</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>03</month>
                <year>2012</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>12</month>
                <year>2011</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>3</month>
                <year>2012</year>
              </pub-date>
              <volume>32</volume>
              <issue>3</issue>
              <fpage>443</fpage>
              <lpage>446</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>05</month>
                  <year>2011</year>
                </date>
                <date date-type="rev-recd">
                  <day>01</day>
                  <month>09</month>
                  <year>2011</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>10</month>
                  <year>2011</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2012 International Society for Cerebral Blood Flow &amp; Metabolism, Inc.</copyright-statement>
                <copyright-year>2012</copyright-year>
                <copyright-holder>International Society for Cerebral Blood Flow &amp; Metabolism, Inc.</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
                  <!--author-paid-->
                  <license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Monoamine oxidase A (MAO-A) is an important target in the pathophysiology and therapeutics of major depressive disorder, aggression, and neurodegenerative conditions. We measured the effect of changes in MAO-A substrate on MAO-A binding in regions implicated in affective and neurodegenerative disease with [<sup>11</sup>C]-harmine positron emission tomography in healthy volunteers. Monoamine oxidase A V<sub>T</sub>, an index of MAO-A density, was decreased (mean: 14%±9%) following tryptophan depletion in prefrontal cortex (<italic>P</italic>&lt;0.031), and elevated (mean: 17%±11%) in striatum following carbidopa–levodopa administration (<italic>P</italic>&lt;0.007). These findings suggest an adaptive role for MAO-A in maintaining monoamine neurotransmitter homeostasis by rapidly compensating fluctuating monoamine levels.</p>
              </abstract>
              <kwd-group>
                <kwd>brain imaging</kwd>
                <kwd>depression</kwd>
                <kwd>dopamine</kwd>
                <kwd>Parkinson's disease</kwd>
                <kwd>positron emission tomography</kwd>
                <kwd>5-HT</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec>
              <title>Introduction</title>
              <p>Monoamine oxidase A (MAO-A) has an important role in processes such as monoamine neurotransmitter metabolism and oxidation as well as the pathophysiology of major depressive disorder (<xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>, <xref ref-type="bibr" rid="bib10">2009</xref>), cigarette smoking (<xref ref-type="bibr" rid="bib4">Fowler <italic>et al</italic>, 1996</xref>), and aggression (<xref ref-type="bibr" rid="bib1">Alia-Klein <italic>et al</italic>, 2008</xref>). The MAO-A site represents a central target for therapeutics of Parkinson's disease and major depressive disorder as reflected by a recent resurgence in MAO-A inhibitor development (<xref ref-type="bibr" rid="bib15">Youdim <italic>et al</italic>, 2006</xref>). Since fluctuations in monoamines can influence mood, motor control, cognition, reward during substance abuse, and predisposition to aggression through neurodevelopment, there is a need to establish whether changes in MAO-A substrate availability affect MAO-A levels in the human brain.</p>
              <p>To address this, we employed two well-established paradigms of changing monoaminergic substrate availability in an [<sup>11</sup>C]-harmine positron emission tomography (PET) study of healthy human subjects: the first was the acute tryptophan depletion (ATD) method to reduce availability of serotonin in prefrontal cortex (<xref ref-type="bibr" rid="bib6">Lieben <italic>et al</italic>, 2004</xref>). The second was sinemet (levi- and carbidopa) administration to increase levels of striatal dopamine in Parkinson's disease (<xref ref-type="bibr" rid="bib2">de la Fuente-Fernandez <italic>et al</italic>, 2001</xref>). We chose [<sup>11</sup>C]-harmine because it is reversible, selective, modeled in humans, has high affinity, no brain penetrant metabolites, and its binding correlates highly with known MAO-A density (<xref ref-type="bibr" rid="bib5">Ginovart <italic>et al</italic>, 2006</xref>). To our knowledge, this is the first study to investigate brain MAO-A binding following acute monaminergic changes in any species.</p>
            </sec>
            <sec sec-type="materials|methods">
              <title>Materials and methods</title>
              <sec>
                <title>Participants</title>
                <p>Nineteen healthy subjects were enrolled (mean age=25±8 years) and randomly assigned to three different groups: (1) ATD (<italic>n</italic>=7), (2) sinemet (<italic>n</italic>=6), and (3) controls (<italic>n</italic>=6). All were physically healthy, nonsmokers, and had no history of neurotoxin use. Participants were screened using the Structured Clinical Interview for DSM- to rule out any Axis I disorders, the Structured Clinical Interview for DSM-IV for Axis II disorders to rule out borderline and antisocial personality disorder, and all underwent urine drug screening on scan days. For each study participant, written consent was obtained. Study and recruitment procedures were approved by the Research Ethics Board for Human Subjects at the Centre for Addiction and Mental Health, University of Toronto.</p>
              </sec>
              <sec>
                <title>Protocol</title>
                <p>The Hamilton Rating Scale for Depression was administered at screening and on scan days. Each participant underwent two PET scans: baseline and postmonoaminergic challenge/depletion/no intervention. Behavioral and mood symptoms were assessed with visual analog scale at screening, and before and after each paradigm on scan days. [<sup>11</sup>C]-harmine PET scans were performed and plasma samples of tryptophan and levidopa/carbidopa were taken 250 minutes after ATD and 150 minutes after intake of oral single sinemet dose (200 mg levodopa, 50 mg carbidopa).</p>
              </sec>
              <sec>
                <title>Image Acquisition and Analysis</title>
                <p>[<sup>11</sup>C]-harmine was of high specific activity (mean 715±461 s.d.  mCi/<italic>μ</italic>mol, 9.9±0.74 mCi at injection time) and administered as an intravenous bolus. An automatic blood sampling system and manual samples were used to measure arterial whole blood and plasma radioactivity (<xref ref-type="bibr" rid="bib5">Ginovart <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>, <xref ref-type="bibr" rid="bib10">2009</xref>). Arterial blood samples were centrifuged, and whole unadulterated plasma samples were injected onto a capture column packed with OASIS resin. Highly polar metabolites and plasma proteins were eluted with 1% CH<sub>3</sub>CN in H<sub>2</sub>O through a coincidence flow detector (Bioscan Flow-Count, Washington DC, USA). Less polar metabolites and [<sup>11</sup>C]-harmine were washed onto an high performance liquid chromatography (HPLC) column (Phenomenex AquaC18, 5 <italic>μ</italic>; Phenomenex, Torrance, CA, USA) and resolved using 30%CH<sub>3</sub>CN/70% H<sub>2</sub>O + 0.1N A.F. pH4 as eluent. Positron emission tomography images were obtained using an HRRT PET camera (full width at half maximum, 3.1 mm; 207 axial sections of 1.2 mm, Siemens Molecular Imaging, Knoxville, TN, USA).</p>
                <p>For the region of interest method, each participant underwent Magnetic Resonance Imaging (GE Signa 1.5-T scanner; T<sub>1</sub>-weighted image; GE Medical Systems, Milwaukee, WI, USA). Regions of interest were delineated on the magnetic resonance imaging using a semiautomated algorithm based on an region of interest template, and a probability of the voxels belonging to the gray matter. Details of scanning, radiotracer synthesis, and image analysis have been described previously and for this study, the Logan method was applied (<xref ref-type="bibr" rid="bib5">Ginovart <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>, <xref ref-type="bibr" rid="bib10">2009</xref>), details for plasma tracer analysis are given in <xref rid="tbl1" ref-type="table">Table 1</xref>. The primary regions of interest were those for which each monoamine manipulation, that is, tryptophan depletion and sinemet administration, most consistently influence substrate levels (i.e., prefrontal cortex (<xref ref-type="bibr" rid="bib6">Lieben <italic>et al</italic>, 2004</xref>) and striatum (<xref ref-type="bibr" rid="bib2">de la Fuente-Fernandez <italic>et al</italic>, 2001</xref>), respectively).</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Both a repeated measures ANOVA (analysis of variance) with MAO-A V<sub>T</sub> as the repeated measure, assessing the effect of intervention and a paired, nonparametric Wilcoxon-signed rank test comparing MAO-A V<sub>T</sub> before and after each paradigm to the test–retest dataset were conducted in each primary region of interest (ATD: prefrontal cortex, carbidopa–levodopa challenge: striatum).</p>
              </sec>
            </sec>
            <sec>
              <title>Results</title>
              <p>As expected, tryptophan (TRP) plasma levels were in the lower range (2.09±1.90 <italic>μ</italic>g/mL, normal range: 11.0 to 15.0 <italic>μ</italic>g/mL) following ATD. After ATD, MAO-A V<sub>T</sub> decreased in all the subjects in the prefrontal cortex, the primary region of interest, with the range being from 3% to 30% of baseline (ANOVA: <italic>P</italic>&lt;0.031; nonparametric: <italic>P</italic>&lt;0.018; see <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
              <p>Levodopa plasma levels and carbidopa levels were in the expected range for a single dose (levodopa: 567±537 ng/mL, carbidopa: 157±146 ng/mL, normal range for total: 513 to 2,002 ng/mL) 150 minutes after dosing. After sinemet administration, MAO-A V<sub>T</sub> increased in all subjects in the striatum, the primary region of interest, with the range being from 6% to 34% (ANOVA: <italic>P</italic>&lt;0.007; nonparametric: <italic>P</italic>&lt;0.028; see <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
              <p>There were no significant differences in MAO-A V<sub>T</sub> values in prefrontal cortex or striatum in test/retest conditions (prefrontal cortex: 5±3, striatum: 8%±5% of baseline; see <xref ref-type="fig" rid="fig1">Figure 1</xref>). Groups did not differ significantly regarding demographic characteristics (age, gender, specific activity injected/injected mass of radiotracer).</p>
            </sec>
            <sec>
              <title>Discussion</title>
              <p>We found decreased MAO-A V<sub>T</sub> following ATD, elevated MAO-A binding after dopamine precursor administration, and no difference in test–retest conditions (<xref ref-type="fig" rid="fig1">Figure 1</xref>). This is the first study to investigate changes in MAO-A binding in the brain after changes in endogenous neurotransmitter. These findings may explain the resiliency of the human brain to environmental conditions of fluctuating monoamines and provide further insight into how therapeutics can work in synergy or oppose this system.</p>
              <p>The general perspective of the brain MAO-A turnover is that it is slow. The earliest time point that has been assessed for change after hormonal manipulations known to influence MAO-A synthesis was at 12 hours (<xref ref-type="bibr" rid="bib7">Manoli <italic>et al</italic>, 2005</xref>). The present study evaluated earlier time points and found changes in MAO-A binding only 2.5 to 4 hours after substrate manipulation. We acknowledge that 85% of the MAO-A V<sub>T</sub> measured with [<sup>11</sup>C]-harmine PET represents specific binding to MAO-A, and changes in specific binding can reflect changes in density or affinity. However, to date, manipulations of MAO-A affinity have not been described in the brain, tremendous (&gt;100%) changes in free and nonspecific binding to account for the V<sub>T</sub> change are extremely unlikely and it is well known that changes in the brain MAO-A levels are highly correlated with MAO-A function (<xref ref-type="bibr" rid="bib14">Saura <italic>et al</italic>, 1992</xref>). Thus, the changes in MAO-A V<sub>T</sub> can be viewed as a compensation opposing the acute change in monoamine levels and as a mechanism to regulate against acute monoamine fluctuations.</p>
              <p>This is the first study to identify a change in the brain MAO-A binding after acute substrate manipulation. We are aware of one previous study conducted in renal tissue: After 48 hours of incubation with dopamine, <xref ref-type="bibr" rid="bib12">Pizzinat <italic>et al</italic> (2003)</xref> reported an increase in MAO-A activity and protein in rat mesangial cells, but not proximal tubule cells. Greater MAO-A binding during monoamine precursor supplement might offer some insight into the limited clinical success of dietary monoaminergic precursor supplements in treating major depressive disorder (<xref ref-type="bibr" rid="bib8">Mendlewicz and Youdim, 1980</xref>) and the relatively temporary benefit of levodopa in Parkinson's. In both circumstances, the administration of the substrate should elicit an increase in MAO-A binding that opposes the therapeutic intent of raising monoamines. Interestingly, the most robust effects on extracellular monoamines occur after direct MAO inhibition (<xref ref-type="bibr" rid="bib3">Ferrer and Artigas, 1994</xref>). The present study also has implications for understanding neural responsivity to ATD: The decrease in MAO-A binding following ATD in healthy volunteers could explain why sad mood is not observed in this group whereas MAO-A binding is elevated in some groups who are vulnerable to mood effects of ATD such as recovered depressed subjects and SSRI-treated depressed subjects (<xref ref-type="bibr" rid="bib11">Neumeister <italic>et al</italic>, 2004</xref>). Future work should consider whether the rise in MAO-A binding is normative in people with a history of MDE (major depressive episodes) after ATD.</p>
              <p>[<sup>11</sup>C]-harmine is increasingly being applied in humans, due to its selectivity, reversibility, and other favorable neuroimaging properties (<xref ref-type="bibr" rid="bib5">Ginovart <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>, <xref ref-type="bibr" rid="bib10">2009</xref>). While some neuroimaging radiotracers have a property of changing binding values in a manner consistent with occupancy by endogenous neurotransmitter, our findings are opposite to the endogenous neurotransmitter occupancy model. This rules out lower endogenous monoamine levels to explain why greater brain MAO-A binding was found during MDE (<xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>), during at risk states for MDE onset such as recovery from MDE (<xref ref-type="bibr" rid="bib10">Meyer <italic>et al</italic>, 2009</xref>) and early postpartum (<xref ref-type="bibr" rid="bib13">Sacher <italic>et al</italic>, 2010</xref>).</p>
              <p>While the present study is limited by the individual group size (<italic>n</italic>=6 to 7 per group), we report a within-subject design, the effects are statistically significant, the alteration in MAO-A binding is present in every individual, and the direction is consistent across the 12 subjects in relation to depletion versus precursor administration. Regional MAO-A V<sub>T</sub> values were in good agreement with previous [<sup>11</sup>C]-harmine PET studies (<xref ref-type="bibr" rid="bib9">Meyer <italic>et al</italic>, 2006</xref>, <xref ref-type="bibr" rid="bib10">2009</xref>; <xref ref-type="bibr" rid="bib13">Sacher <italic>et al</italic>, 2010</xref>), and our control group shows very good test/retest reliability (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The measure of MAO-A used, an index of MAO-A density called MAO-V<sub>T</sub>, reflects total binding, has the advantage of being computationally efficient, and is the most stable and least variable measure of [<sup>11</sup>C]-harmine binding. However, ∼15% of this measure reflects free and nonspecific binding so the magnitude of change in MAO-A binding is underestimated (<xref ref-type="bibr" rid="bib5">Ginovart <italic>et al</italic>, 2006</xref>). Also, while it is theoretically possible that the changes in MAO-AV<sub>T</sub> purely represent free and nonspecific binding, this is unlikely since free and nonspecific binding would have to change by a magnitude of 100% to account for the change in MAO-A V<sub>T</sub> observed.</p>
              <p>A change in MAO-V<sub>T</sub> may also reflect an alteration in affinity of MAO-A in the direction of the change. However, this would not change the interpretation of our data as greater affinity for MAO-A following the carbidopa–levodopa administration and less affinity for MAO-A after the ATD paradigm would still contribute to a dynamic role for MAO-A in a compensating mechanism for protecting the human brain from rapid monoamine fluctuation.</p>
              <p>In conclusion, the present study suggests that MAO-A levels are rapidly regulated by available substrate in the human brain. The decline in MAO-A binding following ATD can be interpreted as a protective strategy against the effect of monoaminergic loss in the healthy human brain, whereas the acute increase in MAO-A binding following a levodopa/carbidopa challenge may be a useful strategy to compensate for a surge in monoamine levels. This also explains why monoamine precursor strategies have a limited duration of beneficial effect and that the most robust manipulations of monoamine levels occur after MAO inhibition.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>This work was supported by GlaxoSmithKline, the Canadian Institutes of Health Research (CIHR), the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Canada Foundation for Innovation (CFI), the Alexander von Humboldt Foundation (AvH), the Ontario Mental Health Foundation (OMHF), and the Ontario Ministry of Research and Innovation.</p>
              </fn>
            </fn-group>
            <notes>
              <p>Drs Meyer, Wilson and Houle have received operating Grant funding for other studies from Eli-Lilly, Lundbeck, GlaxoSmithKline, BristolMyersSquibb and SK Life Sciences and Dr Meyer has consulted to several of these companies. Dr Meyer is developing natural health products to treat high MAO-A states. Dr Meyer is applying for a patent to apply measures of MAO to diagnose or treat mood disorders. Dr Kish receives research funding from US NIH NIDA DA025096 and an expert witness fee to provide an opinion on amphetamine toxicity.</p>
            </notes>
            <ref-list>
              <ref id="bib1">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alia-Klein</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Goldstein</surname>
                      <given-names>RZ</given-names>
                    </name>
                    <name>
                      <surname>Kriplani</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Logan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tomasi</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Telang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Shumay</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Biegon</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Craig</surname>
                      <given-names>IW</given-names>
                    </name>
                    <name>
                      <surname>Henn</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Volkow</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Fowler</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <year>2008</year>
                  <article-title>Brain monoamine oxidase A activity predicts trait aggression</article-title>
                  <source>J Neurosci</source>
                  <volume>28</volume>
                  <fpage>5099</fpage>
                  <lpage>5104</lpage>
                  <pub-id pub-id-type="pmid">18463263</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de la Fuente-Fernandez</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>JQ</given-names>
                    </name>
                    <name>
                      <surname>Sossi</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Jivan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schulzer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Holden</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Ruth</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Calne</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Stoessl</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <year>2001</year>
                  <article-title>Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover</article-title>
                  <source>Ann Neurol</source>
                  <volume>49</volume>
                  <fpage>298</fpage>
                  <lpage>303</lpage>
                  <pub-id pub-id-type="pmid">11261503</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferrer</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Artigas</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <year>1994</year>
                  <article-title>Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain</article-title>
                  <source>Eur J Pharmacol</source>
                  <volume>263</volume>
                  <fpage>227</fpage>
                  <lpage>234</lpage>
                  <pub-id pub-id-type="pmid">7531152</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fowler</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Volkow</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Pappas</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Logan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shea</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Alexoff</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>MacGregor</surname>
                      <given-names>RR</given-names>
                    </name>
                    <name>
                      <surname>Schlyer</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Zezulkova</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Wolf</surname>
                      <given-names>AP</given-names>
                    </name>
                  </person-group>
                  <year>1996</year>
                  <article-title>Brain monoamine oxidase A inhibition in cigarette smokers</article-title>
                  <source>Proc Natl Acad Sci USA</source>
                  <volume>93</volume>
                  <fpage>14065</fpage>
                  <lpage>14069</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ginovart</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Meyer</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Boovariwala</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hussey</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Rabiner</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Houle</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>AA</given-names>
                    </name>
                  </person-group>
                  <year>2006</year>
                  <article-title>Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain</article-title>
                  <source>J Cereb Blood Flow Metab</source>
                  <volume>26</volume>
                  <fpage>330</fpage>
                  <lpage>344</lpage>
                  <pub-id pub-id-type="pmid">16079787</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lieben</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Blokland</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Westerink</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Deutz</surname>
                      <given-names>NE</given-names>
                    </name>
                  </person-group>
                  <year>2004</year>
                  <article-title>Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat</article-title>
                  <source>Neurochem Int</source>
                  <volume>44</volume>
                  <fpage>9</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="pmid">12963083</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Manoli</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Le</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Alesci</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>McFann</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Su</surname>
                      <given-names>YA</given-names>
                    </name>
                    <name>
                      <surname>Kino</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Chrousos</surname>
                      <given-names>GP</given-names>
                    </name>
                    <name>
                      <surname>Blackman</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <year>2005</year>
                  <article-title>Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells</article-title>
                  <source>FASEB J</source>
                  <volume>19</volume>
                  <fpage>1359</fpage>
                  <lpage>1361</lpage>
                  <pub-id pub-id-type="pmid">15946989</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mendlewicz</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Youdim</surname>
                      <given-names>MB</given-names>
                    </name>
                  </person-group>
                  <year>1980</year>
                  <article-title>Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness</article-title>
                  <source>J Affect Disord</source>
                  <volume>2</volume>
                  <fpage>137</fpage>
                  <lpage>146</lpage>
                  <pub-id pub-id-type="pmid">6448885</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyer</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Ginovart</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Boovariwala</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sagrati</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hussey</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Garcia</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Praschak-Rieder</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Houle</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <year>2006</year>
                  <article-title>Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression</article-title>
                  <source>Arch General Psychiatry</source>
                  <volume>63</volume>
                  <fpage>1209</fpage>
                  <lpage>1216</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib10">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyer</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Sagrati</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Miler</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Rusjan</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Bloomfield</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sacher</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Voineskos</surname>
                      <given-names>AN</given-names>
                    </name>
                    <name>
                      <surname>Houle</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <year>2009</year>
                  <article-title>Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery and recurrence</article-title>
                  <source>Arch General Psychiatry</source>
                  <volume>66</volume>
                  <supplement>(12</supplement>
                  <fpage>1304</fpage>
                  <lpage>1312</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib11">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neumeister</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Nugent</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Waldeck</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Geraci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schwarz</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bonne</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Bain</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Luckenbaugh</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Herscovitch</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Drevets</surname>
                      <given-names>WC</given-names>
                    </name>
                  </person-group>
                  <year>2004</year>
                  <article-title>Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls</article-title>
                  <source>Arch General Psychiatry</source>
                  <volume>61</volume>
                  <fpage>765</fpage>
                  <lpage>773</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib12">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pizzinat</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Marchal-Victorion</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Maurel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ordener</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bompart</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Parini</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <year>2003</year>
                  <article-title>Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors</article-title>
                  <source>Am J Physiol</source>
                  <volume>284</volume>
                  <fpage>F167</fpage>
                  <lpage>F174</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib13">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sacher</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Houle</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rusjan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hassan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bloomfield</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Stewart</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Meyer</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <year>2010</year>
                  <article-title>Elevated brain monoamine oxidase A binding in the early postpartum period</article-title>
                  <source>Arch General Psychiatry</source>
                  <volume>67</volume>
                  <fpage>468</fpage>
                  <lpage>474</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib14">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saura</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kettler</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Da Prada</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Richards</surname>
                      <given-names>JG</given-names>
                    </name>
                  </person-group>
                  <year>1992</year>
                  <article-title>Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 <italic>in vitro</italic>: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain</article-title>
                  <source>J Neurosci</source>
                  <volume>12</volume>
                  <fpage>1977</fpage>
                  <lpage>1999</lpage>
                  <pub-id pub-id-type="pmid">1578281</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib15">
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Youdim</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Edmondson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Tipton</surname>
                      <given-names>KF</given-names>
                    </name>
                  </person-group>
                  <year>2006</year>
                  <article-title>The therapeutic potential of monoamine oxidase inhibitors</article-title>
                  <source>Nat Rev</source>
                  <volume>7</volume>
                  <fpage>295</fpage>
                  <lpage>309</lpage>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="fig1">
              <label>Figure 1</label>
              <caption>
                <p>Monoamine oxidase A distribution volumes (MAO-A V<sub>T</sub>) changed in parallel with changes in endogenous substrate in contrast to test/retest MAO-A V<sub>T</sub> values that did not change. In healthy subjects, acute tryptophan depletion was associated with a reduction in MAO-A V<sub>T</sub>, which ranged from 3% to 30% and this effect was statistically significant (repeated measure analysis of variance (ANOVA): <italic>P</italic>&lt;0.031<sup>*</sup>; paired nonparametric Wilcoxon-signed rank test, <italic>P</italic>=0.018<sup>*</sup>) for the primary region of interest (prefrontal cortex). Oral administration of the dopamine precursor (levodopa/carbidopa) was associated with an increase in MAO-A V<sub>T</sub>, which ranged from 6% to 34% and this effect was statistically significant (repeated measure ANOVA: <italic>P</italic>&lt;0.007<sup>**</sup>; paired nonparametric Wilcoxon-signed rank test, <italic>P</italic>=0.028<sup>**</sup>) for the primary region of interest (striatum).</p>
              </caption>
              <graphic xlink:href="jcbfm2011184f1"/>
            </fig>
            <table-wrap id="tbl1">
              <label>Table 1</label>
              <caption>
                <title>Comparison of tracer properties in plasma in all three groups</title>
              </caption>
              <table frame="hsides" rules="groups" border="1">
                <colgroup>
                  <col align="left"/>
                  <col align="char" char="."/>
                  <col align="char" char="."/>
                  <col align="char" char="."/>
                </colgroup>
                <thead valign="bottom">
                  <tr>
                    <th align="left" valign="top" charoff="50">
                      <italic>Percentage change of parent fraction</italic>
                      <xref ref-type="fn" rid="t1-fn1">a</xref>
                      <italic>before and after each manual sample after minute</italic>
                    </th>
                    <th align="center" valign="top" char="." charoff="50">
                      <italic>Carbidope/ levidopa group</italic>
                    </th>
                    <th align="center" valign="top" char="." charoff="50">
                      <italic>Acute tryptophan depletion group</italic>
                    </th>
                    <th align="center" valign="top" char="." charoff="50">
                      <italic>Test–retest group</italic>
                    </th>
                  </tr>
                </thead>
                <tbody valign="top">
                  <tr>
                    <td align="left" valign="top" charoff="50">5 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">12%</td>
                    <td align="char" valign="top" char="." charoff="50">14%</td>
                    <td align="char" valign="top" char="." charoff="50">5%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">10 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">8%</td>
                    <td align="char" valign="top" char="." charoff="50">5%</td>
                    <td align="char" valign="top" char="." charoff="50">2%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">20 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">3%</td>
                    <td align="char" valign="top" char="." charoff="50">3%</td>
                    <td align="char" valign="top" char="." charoff="50">2%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">30 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">2%</td>
                    <td align="char" valign="top" char="." charoff="50">7%</td>
                    <td align="char" valign="top" char="." charoff="50">2%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">45 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">1%</td>
                    <td align="char" valign="top" char="." charoff="50">0.005%</td>
                    <td align="char" valign="top" char="." charoff="50">1%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">60 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">4%</td>
                    <td align="char" valign="top" char="." charoff="50">4%</td>
                    <td align="char" valign="top" char="." charoff="50">7%</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" charoff="50">90 minutes</td>
                    <td align="char" valign="top" char="." charoff="50">1%</td>
                    <td align="char" valign="top" char="." charoff="50">5%</td>
                    <td align="char" valign="top" char="." charoff="50">5%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="t1-fn1">
                  <label>a</label>
                  <p>Parent fraction: percentage of parent (nCi/g) relative to metabolites (nCi/g).</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
